Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 9

1.

Five-year efficacy and safety analysis of the Adenoma Prevention with Celecoxib Trial.

Bertagnolli MM, Eagle CJ, Zauber AG, Redston M, Breazna A, Kim K, Tang J, Rosenstein RB, Umar A, Bagheri D, Collins NT, Burn J, Chung DC, Dewar T, Foley TR, Hoffman N, Macrae F, Pruitt RE, Saltzman JR, Salzberg B, Sylwestrowicz T, Hawk ET; Adenoma Prevention with Celecoxib Study Investigators.

Cancer Prev Res (Phila). 2009 Apr;2(4):310-21. doi: 10.1158/1940-6207.CAPR-08-0206. Epub 2009 Mar 31.

2.

Tolerability of selective cyclooxygenase 2 inhibitors used for the treatment of rheumatological manifestations of inflammatory bowel disease.

Miao XP, Li JS, Ouyang Q, Hu RW, Zhang Y, Li HY.

Cochrane Database Syst Rev. 2014 Oct 23;(10):CD007744. doi: 10.1002/14651858.CD007744.pub2. Review.

PMID:
25340915
3.

New, long-term insights from the Adenoma Prevention with Celecoxib Trial on a promising but troubled class of drugs.

Dubois RN.

Cancer Prev Res (Phila). 2009 Apr;2(4):285-7. doi: 10.1158/1940-6207.CAPR-09-0038. Epub 2009 Mar 31. Review. No abstract available.

4.

Celecoxib: a review of its use for symptomatic relief in the treatment of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis.

McCormack PL.

Drugs. 2011 Dec 24;71(18):2457-89. doi: 10.2165/11208240-000000000-00000. Review.

PMID:
22141388
5.

[Are there any differences in the cardiovascular tolerance between classical NSAIDs and coxibs?].

Valat JP, Deray G, Héloire F.

Presse Med. 2006 Sep;35(9 Spec No 1):1S25-34. Review. French.

PMID:
17078592
6.

Risk of cardiovascular events and celecoxib: a systematic review and meta-analysis.

Caldwell B, Aldington S, Weatherall M, Shirtcliffe P, Beasley R.

J R Soc Med. 2006 Mar;99(3):132-40. Review.

7.

Chemoprevention of colorectal cancer: systematic review and economic evaluation.

Cooper K, Squires H, Carroll C, Papaioannou D, Booth A, Logan RF, Maguire C, Hind D, Tappenden P.

Health Technol Assess. 2010 Jun;14(32):1-206. doi: 10.3310/hta14320. Review.

8.
9.

Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors for primary prevention of colorectal cancer: a systematic review prepared for the U.S. Preventive Services Task Force.

Rostom A, Dubé C, Lewin G, Tsertsvadze A, Barrowman N, Code C, Sampson M, Moher D; U.S. Preventive Services Task Force.

Ann Intern Med. 2007 Mar 6;146(5):376-89. Review.

PMID:
17339623

Supplemental Content

Support Center